FEBRUARY 18, 2012

ASCO 2008 Annual Meeting - Safety and Efficacy of Sorafenib in Elderly Patients (pts) >65 Years: A Subset Analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America

E-mail Print

Abstract No.: 5045
Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 5045)
Author(s): R. M. Bukowski, W. M. Stadler, R. A. Figlin, J. J. Knox, N. Gabrail, D. F. McDermott, L. Cupit, W. H. Miller, J. D. Hainsworth, C. W. Ryan, Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America




Your session will expire in 8 hours requiring you to log in each day to view content.
Share |